Meanwhile positive thoughts the impact of the usa today exposure of recce as an answer to resistant bacterial infections while all other 60 plus year old antibiotic penicillin derivatives have failed is right before us watch this stock i expect rightly so, for it to be on the radar of astute bio investors right now and climbing the exposure via the lead presenter at the world bio conference in the usa is just starting to get going in terms of investor positioning for early investors in the late first quarter and into the second quarter of next year this tightly held stock will reflect demand for this breakthrough product - irresistible antibiotic! i dont need to espouse its value but the demand will be huge like the margin good luck in the new year entering this stock with not s lot of free float on issue and no need for further funding for the first in human clinical trials a relatively low cost fast track pathway to fda ultimate approval will really shine this stock
ps i already hold a bit and increasingly am encouraged after last week performance to buy more as it seems to me some bigger buyers are finally waking up
RCE Price at posting:
36.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)